Walleye Trading LLC cut its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI – Get Rating) by 19.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,894 shares of the company’s stock after selling 3,823 shares during the quarter. Walleye Trading LLC’s holdings in Aerie Pharmaceuticals were worth $119,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. US Bancorp DE increased its position in shares of Aerie Pharmaceuticals by 174.4% in the first quarter. US Bancorp DE now owns 3,685 shares of the company’s stock valued at $34,000 after buying an additional 2,342 shares in the last quarter. Advisor Group Holdings Inc. increased its position in shares of Aerie Pharmaceuticals by 33.9% in the first quarter. Advisor Group Holdings Inc. now owns 6,863 shares of the company’s stock valued at $62,000 after buying an additional 1,739 shares in the last quarter. Amalgamated Bank purchased a new stake in shares of Aerie Pharmaceuticals in the first quarter valued at approximately $63,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Aerie Pharmaceuticals in the second quarter valued at approximately $95,000. Finally, Running Point Capital Advisors LLC purchased a new stake in shares of Aerie Pharmaceuticals in the first quarter valued at approximately $99,000. 95.94% of the stock is owned by institutional investors and hedge funds.
Aerie Pharmaceuticals Stock Up 0.1 %
Shares of NASDAQ:AERI opened at $15.25 on Friday. The business has a fifty day moving average of $15.19 and a two-hundred day moving average of $10.98. The stock has a market cap of $753.66 million, a P/E ratio of -19.80 and a beta of -0.06. Aerie Pharmaceuticals, Inc. has a 52-week low of $4.81 and a 52-week high of $15.37.
Analysts Set New Price Targets
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.
- Get a free copy of the StockNews.com research report on Aerie Pharmaceuticals (AERI)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.